Anthem Biosciences IPO GMP Today: Why Investors Are Buzzing About This IPO

Hook Headline: Anthem Biosciences IPO GMP Today Surges 27%—Is This the Hottest IPO of July?

IPO Overview: Anthem Biosciences Ltd Makes a Bold Market Entry

Anthem Biosciences Ltd, a leading CRDMO headquartered in Bengaluru, has made headlines with its ₹3,395 crore initial public offering (IPO). Entirely structured as an offer-for-sale with no fresh issue, the IPO opened on July 14 and closed on July 16, 2025. The price band has been fixed between ₹540 and ₹570, with a minimum lot size of 26 shares. Shares are expected to be listed on July 21, 2025, with KFin Technologies as the registrar and major investment banks like JM Financial, Citigroup Global Markets, JP Morgan India, and Nomura managing the issue.

Anthem Biosciences IPO GMP Today: Real-Time Market Sentiment

As of July 16, 2025, the Grey Market Premium (GMP) for the Anthem Biosciences IPO stands at ₹156, suggesting a possible listing price of ₹726. This reflects an impressive premium of 27.37% over the issue’s upper price band, highlighting strong investor enthusiasm. Over the past five days, the GMP trend has shown a steady rise—from ₹99 on July 12, increasing to ₹100 on July 13, then ₹116 on July 14, a spike to ₹155 on July 15, and finally ₹156 today. This trajectory mirrors the growing interest and market confidence surrounding the IPO.

Subscription Status: Strong Demand Across Segments

The IPO witnessed widespread participation from various investor categories. Overall, it was subscribed 29 times. The Qualified Institutional Buyers (QIBs) category recorded an overwhelming subscription of 65.72 times, followed closely by Non-Institutional Investors (NIIs) at 36.39 times. Retail Investors also showed keen interest with a subscription of 4.60 times, while the employee category registered a 5.11 times subscription. This level of demand underscores the optimism and credibility that Anthem Biosciences commands in the market.

Why This Is Trending Right Now

The IPO is trending today for several compelling reasons. Anthem Biosciences recently raised ₹1,016 crore from 60 anchor investors, including high-profile names like Abu Dhabi Investment Authority and Norway’s Government Pension Fund Global. Over just two days, the GMP saw a 50% jump, reflecting widespread anticipation of substantial listing gains. Influential brokerage firms such as SBI Securities, Anand Rathi, and Canara Bank Securities have issued bullish ‘Subscribe’ recommendations, pointing to Anthem’s robust financial performance and strategic market positioning. For FY25, the company reported an impressive net profit of ₹451.26 crore on revenues of ₹1,930.29 crore, further validating investor interest.

Business Strengths of Anthem Biosciences Ltd

Anthem stands out with its comprehensive CRDMO capabilities, spanning drug discovery to commercial manufacturing. It holds critical international certifications including USFDA, ANVISA, and ISO, ensuring global compliance and quality standards. The company boasts a high 95.59% success rate across fee-for-service contracts, working with over 675 clients across 44 countries. Its forward-thinking focus on green chemistry, peptides, fermentation-based APIs, and specialty ingredients gives it a distinctive edge in the biotechnology sector.

SEO-Focused Subtopics

Anthem Biosciences GMP: A Signal of Strong Demand

The current GMP of ₹156 is a strong indicator of high investor confidence, pointing toward a successful listing. It suggests that market participants see significant value in the company and are willing to pay a premium before the shares even hit the exchanges.

IPO Pricing Analysis

Priced at a price-to-earnings (P/E) ratio of 70.9 times its FY25 earnings, the IPO may appear steep at first glance. However, when compared to competitors in the CRDMO space, the valuation is viewed as reasonable given Anthem’s profitability, scale, and potential for future growth.

How Anthem’s GMP Compares to Other IPOs

In the current IPO landscape, Anthem Biosciences is demonstrating one of the strongest grey market performances. While many recent IPOs have struggled with volatility and tepid demand, Anthem’s GMP streak sets it apart, signaling strong secondary market confidence.

What Makes Anthem Biosciences Ltd Unique?

Anthem’s business model is built around the fee-for-service structure, appealing to small and mid-sized biotech firms globally. Its specialization in fermentation technologies and environmentally sustainable solutions marks it as a pioneer in its field. The company's proactive approach to innovation positions it well for continued success.

Frequently Asked Questions (FAQ)

Q1: What is Anthem Biosciences IPO GMP today?

As of July 16, 2025, the IPO GMP is ₹156, representing a projected 27.37% premium over the issue price.

Q2: When will Anthem Biosciences IPO list?

The IPO is scheduled to list on July 21, 2025, on both the BSE and NSE.

Q3: Should I invest in this IPO?

Analysts from top brokerages have suggested a ‘Subscribe’ rating, noting the company’s solid financials and growth prospects.

Q4: What is the minimum amount required to apply?

Retail investors must invest ₹14,040 to apply for a single lot of 26 shares.

Q5: What is GMP in IPO terms?

Grey Market Premium refers to the premium at which IPO shares are traded in the unofficial market before listing, often signaling market expectations.

Conclusion: Is Anthem Biosciences IPO a Golden Opportunity?

With high subscription numbers, surging GMP, and endorsements from leading analysts, Anthem Biosciences IPO appears to be one of the most attractive offerings of the season. The company’s leadership in CRDMO services, commitment to sustainability, and proven financial performance make it a compelling bet for both listing gains and long-term investment. Given all signs, it’s no surprise that this IPO is dominating market conversations and investor dashboards across India.